Urinary urge incontinence

Bibliography

• Urinary Incontinence in Adults. Clinical Practice Guideline. Agency for Healthcare Policy and Research, US Department of Health and Human Services (1996).
   Google Scholar
• ••Good overview of incontinence and current clinical practice.
   Google Scholar
• BROCKLEHURST JC: Urinary incontinence in the community - analysis of a MORI poll. Br. Med. J. (1993) 306:832–834.
   PubMed Web of Science ®Google Scholar
• THOMAS TM, PLYMAT KR, BLANNIN J, MEADE TW: Prevalence of urinary incontinence. Br. Med. J. (1980) 281:1243–1245.
   PubMed Web of Science ®Google Scholar
• HU T, GABELKO K, WEIS KA, et al.: Clinical guidelines and cost implications - the case of urinary incontinence. Geriat. Nephrol. Urol. (1994) 4:85–91.
   Google Scholar
• ABRAMS P, BLAIVAS JG, STANTON SL, ANDERSEN JT: The standardisation of terminology of lower urinary tract function. World J. Urol. (1989) 6:233–245.
   Web of Science ®Google Scholar
• BLAIVAS JG: Pathophysiology of lower urinary tract dysfunction. Urol. Clin. North Am. (1985) 12:215–224.
   PubMed Web of Science ®Google Scholar
• WILLIAMS ME, PANNILL FC: Urinary incontinence in the elderly: pathophysiology, diagnosis and treatment. Ann. Intern. Med. (1982) 97:895–907.
   PubMed Web of Science ®Google Scholar
• HAMPEL C, WIENHOLD D, BENKEN N, EGGERSMANN C, THUROFF JW. Definition of overactive bladder and epidemiology of urinary incontinence. Urology (1997) 50(6A Suppl.):4–14.
   PubMed Web of Science ®Google Scholar
• ECKFORD SD, KEANE DP: Management of detrusor instability. Br. J. Hosp. Med. (1993) 49:282–285.
   PubMed Web of Science ®Google Scholar
• MOORE KH, HAY DM, IMRIE AE, WATSON AMG: Oxybutynin hydrochloride (3 mg) in the treatment of idiopathic detrusor instability. Br. J. Urol. (1990) 66:479–485.
   PubMedGoogle Scholar
• •Very informative clinical study with good discussion of results.
   Google Scholar
• THUROFF JW, BUNKE B, EBNER A, et al.: Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J. Urol. (1991) 145 (4) :813-816. Discussion 816–817.
   Google Scholar
• •Very informative clinical study with good discussion of results.
   Google Scholar
• HOLMES DM, MONTZ FJ, STANTON SL: Oxybutynin versus propantheline in the management of detrusor instability. A patient-regulated variable dose trial. Br. J. Obstet. Gynaecol. (1989) 96:607–612.
   PubMedGoogle Scholar
• RITCH AES, CASTLEDEN CM, GEORGE CF, HALL MRP: A second look at emepronium bromide in urinary incontinence. Lancet (1977) VOL:504–506.
   PubMed Web of Science ®Google Scholar
• ANDERSEN JR, LOSE G, NORGAARD M, STIMPEL H, ANDERSEN JT: Terodiline, emepronium bromide or placebo for treatment of female detrusor overactivity A randomised double-blind cross-over study. Br. J. Urol. (1988) 61:310–313.
   PubMedGoogle Scholar
• SALVATORE S, KHULLAR V, CARDOZO L, et al.: Long-term outcome of women with detrusor instability treated with oxybutynin. Neurourol. Urodynam. (1995) 14:460–462.
   Google Scholar
• TESTA R, GUARNERI L, BERNASCONI P, et al.: Effects of terflavoxate on stimulated contractions of urinary bladder in vitro. Arzneimittelforschung (1993) 43 (2):122–128.
   PubMed Web of Science ®Google Scholar
• MILANI R, SCALAMBRINO S, MILIA R, et al.: Double-blind crossover comparison of flavoxate and oxybutynin in women affected by urinary urge syndrome. Int. Urogynecol. J. (1993) 4:3–8.
   Google Scholar
• MEYHOFF HH, GERSTENBERG TC, NORDLING J: Placebo: the drug of choice in female motor incontinence Br. J. Urol. (1983) 55 (1) 34–37.
   PubMedGoogle Scholar
• ROBINSON JM, BROCKLEHURST JC: Emepronium bromide and flavoxate hydrochloride in the treatment of urinary incontinence associated with detrusor instability in elderly women. Br. J. Urol. 55 (4) :371–376.
   PubMedGoogle Scholar
• ZEEGERS AGM, KIESSWETTER H, KRAMER AEJL, JONAS U: Conservative therapy of frequency, urgency and urge incontinence: a double-blind clinical trial of flavoxate hydrochloride, oxybutynin chloride, emepronium bromide and placebo. World J. Urol. (1987) 5:57–61.
   Web of Science ®Google Scholar
• CHAPPLE C, PARKHOUSE H, GARDENER C, MILROY EJG. Double-blind, placebo-controlled, cross-over study of flavoxate in the treatment of idiopathic detrusor instability. Br. J. Urol. (1990) 66:491–494.
   PubMedGoogle Scholar
• MAZUR D, WEHNERT J, DORSCHNER WGS, HERFURTH G, ALKEN RG: Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. Scand. J. Urol. Nephrol. (1995) 29:289–294.
   PubMed Web of Science ®Google Scholar
• GIERSSON G, FALL M, LINDSTROM S: Cystometric subtypes of bladder overactivity: A retrospective analysis of 501 patients. mt. Urogynecol. J. (1993) 4:186–193.
   Google Scholar
• CHAI TC, STEERS WD: Neurophysiology of micturition and continence. Urodynamics (1996) 23:221–236.
   Google Scholar
• ••Comprehensive review of the neuronal control of bladder function.
   Google Scholar
• MAGGI CA, MELI A: The role of neuropeptides in the regulation of the micturition reflex. J. Autonom. Pharmacol. (1986) 6:133–162.
   PubMedGoogle Scholar
• MORRISON JFB: The physiological mechanisms involved in bladder emptying. Scand. J. Urol. Nephrol. (1997) 184 (Suppl.):15–18.
   PubMedGoogle Scholar
• DENNY-BROWN D, ROBERTSON EG: On the physiology of micturition. Brain (1933) 56:149–190.
   Google Scholar
• IGGO A: Tension receptors in the stomach and the urinary bladder. J. Physiol. (1955)128:593–607.
   PubMed Web of Science ®Google Scholar
• HULSEBOSCH CE, COGGESHALL RE: An analysis of the axon populations in the nerves to the pelvic viscera in the rat. J. Comp. Neurol. (1982) 211:1–10.
   PubMed Web of Science ®Google Scholar
• MORGAN C, NADELHAFT I, DE GROAT WC: The distribution of visceral primary afferents from the pelvic nerve within Lissauer's tract and the spinal grey matter and its relationship to the sacral parasympathetic nucleus. J. Comp. Neurol. (1981) 201:415–440.
   PubMed Web of Science ®Google Scholar
• STEERS WD, CIAMBOTTI J, ETZEL B, ERDMAN S, DE GROAT WC: Alterations in afferent pathways from the urinary bladder of the rat in response to partial urethral obstruction. J. Comp. Neurol. (1991) 310:401–410.
   PubMed Web of Science ®Google Scholar
• MOORE KH, GILPIN SA, DIXON JS, RICHMOND DH, SUTHERST JR: Increase in presumptive sensory nerves of the urinary bladder in idiopathic detrusor instability. Br. J. Urol. (1992) 70(4):370–372.
   PubMedGoogle Scholar
• CHANDIRAMANI VA, PETERSON T, DUTHIE GS, FOWLER CJ: Urodynamic changes during therapeutic intravesical instillations of capsaicin. Br. J. Urol. (1996) 77(6) :792–797.
   PubMedGoogle Scholar
• MAGGI CA, BARBANTI G, SANTICIOLI P, et al.: Cystometric evidence that capsaicin-sensitive nerves modulate the afferent branch of micturition reflex in humans. J. Urol. (1989) 142(1):150–154.
   PubMed Web of Science ®Google Scholar
• ••First report of potential benefit of afferent modulation in treatment of UUI.
   Google Scholar
• MAGGI CA, GIULIANI S, SANTICIOLI P, ABELLI L, GIACHETTI A: Facilitation of reflex micturition by intravesical administration of [beta Ala8[ -neurokinin A (4-10), a selective NK-2 tachykinin receptor agonist. J. Urol. (1991) 145(1):184–187.
   PubMed Web of Science ®Google Scholar
• BUSHFIELD M, METCALFE M, NAYLOR AM: Activation of the micturition reflex by NK2 receptor stimulation in the anaesthetized guinea-pig. Br. J. Pharmacol. (1995) 115(6) :875–882.
   PubMed Web of Science ®Google Scholar
• DION S, ROUISSI N, NANTEL F, et al.: Receptors for neurokinins in human bronchus and urinary bladder are of the NK-2 type. Eur. J. Pharmacol. (1990) 178(4:215–219.
   PubMed Web of Science ®Google Scholar
• GIULIANI S, PATACCHINI R, BARBANTI G, et al.: Characteristics of the tachykinin NK2 receptor in the human urinary bladder by means of selective neurokinin antagonists and peptidase inhibitors. J. Pharmacol. Exp. Ther. (1993) 267:590–595.
   PubMed Web of Science ®Google Scholar
• LANGLEY JN, ANDERSON HS: The innervation of the pelvic nerve and adjoining viscera. Part II. J. Physiol. (1895) 19:71–84.
   PubMedGoogle Scholar
• ••First characterisation of the innervation of the bladder. Historically significant paper.
   Google Scholar
• GOSLING JA, DIXON JS: The structure and innervation of smooth muscle in the wall of the bladder and proximal urethra. Br. J. Urol. (1975) 47:549–558.
   PubMedGoogle Scholar
• CAULFIELD MP: Muscarinic receptors - characterization, coupling and function. Pharmacol. Ther. (1993) 58:319–379.
   PubMed Web of Science ®Google Scholar
• ••Excellent review on muscarinic receptor distribution and function.
   Google Scholar
• NEWGREEN DT, NAYLOR AM: Characterisation of functional muscarinic receptors in human bladder. Br. J. Pharmacol. (1996) 119:45P.
   Web of Science ®Google Scholar
• LEAHY DJ, NEWGREEN DT, STORRS JT, NAYLOR AM: Characterisation of functional muscarinic receptors in human submandibular salivary gland. Br. J. Pharmacol. (1997) 120:204P.
   PubMed Web of Science ®Google Scholar
• SIBLEY GN: A comparison of spontaneous and nerve-mediated activity in bladder muscle from man, pig and rabbit. J. Physiol. (1984) 354:431–443.
   PubMed Web of Science ®Google Scholar
• •Extensive experimental study of nerve-stimulated bladder contraction.
   Google Scholar
• BAYLISS M, NEWGREEN D, FRY CH: Changes to the functional properties of human detrusor smooth muscle and its innervation with disease. J. Physiol. (1998).
   Google Scholar
• SMET PJ, MOORE KH, JONAVICIUS J: Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder. Lab. Invest. (1997) 77(1)37–49.
   PubMed Web of Science ®Google Scholar
• ANDERSSON K-E: The overactive bladder: pharmacologic basis of drug treatment. Urology (1997) 50(6A):74–84.
   PubMed Web of Science ®Google Scholar
• ••Good review of bladder pharmacology.
   Google Scholar
• RUD T, ANDERSSON KE, ULMSTEN U: Effects of nifedipine in women with unstable bladders. Urol. Int. (1979) 34:421–429.
   PubMed Web of Science ®Google Scholar
• NURSE DE, RESTORICK JM, MUNDY AR: The effect of cromakalim on the normal and hyper-reflexic human detrusor muscle. Br. J. Urol. (1991) 68 (1):27–31.
   PubMedGoogle Scholar
• OYASU H, YAMAMOTO T, SATO N, et al.: Urinary bladder-selective action of the new antimuscarinic compound vamicamide. Arzneimittelforschung (1994) 44 (11) :1242–1249.
   PubMed Web of Science ®Google Scholar
• MORIKAWA K, OSHITA M, YAMAZAKI M, et al.: Pharmacological studies of the new centrally-acting muscle relaxant 4'- ethyl-2-methyl-3-pyrrolidinopropiophenone hydrochloride. Arzneimittelforschung (1987) 37(3):331–336.
   PubMed Web of Science ®Google Scholar
• MORIKAWA K, HASHIMOTO S, YAMAUCHI T, et al.: Inhibitory effect of inaperisone hydrochloride (inaperisone), a new centrally-acting muscle relaxant, on the micturition reflex. Eur. J. Pharmacol. (1992) 213(3):409–415.
   PubMed Web of Science ®Google Scholar
• SAKITAMA K, OZAWA Y, AOTO N, NAKAMURA K, ISHIKAWA M: Pharmacological properties of NK433, a new centrally-acting muscle relaxant. Eur. J. Pharmacol. (1995) 273 (1-2):47–56.
   PubMed Web of Science ®Google Scholar
• HAMADA K, SASAKI Y, TANIGUCHI N, et al.: Anticholinergic and calcium antagonistic activities of NS-21 contribute to the inhibition of rat urinary bladder contractions. Gen. Pharmacol. (1997) 29(5):771–778.
   PubMedGoogle Scholar
• ALABASTER VA: Discovery and development of selective M, antagonists for clinical use. Life Sci. (1997) 60:1053–1060.
   PubMed Web of Science ®Google Scholar
• NEWGREEN DT, NAYLOR AM: Comparison of the functional muscarinic receptor selectivity of darifenacin with tolterodine and oxybutynin. Br. J. Pharmacol. (1996) 117:107P.
   Web of Science ®Google Scholar
• NEWGREEN DT, ANDERSON CWP, CARTER AJ, NAYLOR AM: Darifenacin - a novel bladder-selective muscarinic antagonist for the treatment of urge incontinence. Neurourol. Urodynam. (1995) 14:555–557.
   Google Scholar
• NILVEBRANT L, ANDERSSON KE, GILLBERG PG, STAHL M, SPARF B: Tolterodine - a new bladder-selective antimuscarinic agent. Eur. J. Pharmacol. (1997) 327(2-3):195–207.
   PubMed Web of Science ®Google Scholar
• JONAS U, HOFNER K, MADERSBACHER H, HOLMDAHL TH: Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World J. Urol. (1997) 15 (2) :144–151.
   PubMed Web of Science ®Google Scholar
• APPELL RA: Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis. Urology (1997) 50 (6A):90–96.
   PubMed Web of Science ®Google Scholar
• EMONDS-ALT X, VILAIN P, GOULAOUIC P, et al.: A potent and selective non-peptide antagonist of the neurokinin A (NK) receptor. Life Sci. (1992) 50(15):L101–L106.
   Web of Science ®Google Scholar
• •First example of a non-peptide NK, antagonist.
   Google Scholar
• HEPPNER TJ, BONEV A, LI JH, KAU ST, NELSON MT: Zeneca ZD6169 activates ATP-sensitive K+ channels in the urinary bladder of the guinea pig. Pharmacology (1996) 53(3):170–179
   Google Scholar
• HOWE BB, HALTERMAN TJ, YOCHIM CL, et al.: ZENECA ZD6169: a novel K,Tp channel opener with in vivo selectivity for urinary bladder. J. Pharmacol. Exp. Ther. (1995) 274(2):884–890.
   PubMed Web of Science ®Google Scholar
• STEWART DA, TAYLOR J, GHOSH S, et al.: Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur. J. Clin. Pharmacol. (1992) 42(6):577–580.
   PubMed Web of Science ®Google Scholar
• TAYLOR MC, BATES CP: A double-blind crossover trial of Baclofen - a new treatment for the unstable bladder syndrome. Br. J. UroL (1979) 51:504–505.
   PubMedGoogle Scholar